Companion Animal Vaccines Market Forecast for Core and Non-Core Vaccines 2032
- sachi toshniwal
- 1 day ago
- 4 min read
The companion animal vaccines market focuses on vaccines developed to protect pets such as dogs and cats from various infectious diseases. These vaccines play a vital role in preventive veterinary care, helping to control diseases like rabies, distemper, and parvovirus. The market is growing steadily due to rising pet ownership, increasing awareness about animal health, and advances in veterinary medicine. Pet humanization trends and the expansion of veterinary services also support demand. North America leads the market, while Asia-Pacific is witnessing rapid growth due to rising pet adoption and improving access to animal healthcare.
According to Fortune Business Insights, the global companion animal vaccines market was valued at USD 5.43 billion in 2024 and is projected to grow from USD 5.67 billion in 2025 to USD 8.71 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.3% during the forecast period. In 2024, North America dominated the market with a 43.46% share.
Top Companies in the Market
Elanco (U.S.)
HIPRA (Spain)
Boehringer Ingelheim International GmbH (Germany)
Virbac (France)
Merck Animal Health (U.S.)
Zoetis Services LLC (U.S.)
Ceva (France)
NEOGEN CORPORATION (U.S.)
Hester Biosciences Limited (India)
Key Industry Development
In June 2024, Merck Animal Health launched its NOBIVAC NXT Rabies portfolio in Canada, including NOBIVAC NXT Feline‑3 Rabies and NOBIVAC NXT Canine‑3 Rabies. This strategic product rollout underscores the company’s leadership in preventive pet healthcare and commitment to expanding vaccine coverage in key regional markets.
Market Drivers & Restraints
Market Drivers
The primary growth drivers fueling the expansion of the companion animal vaccines market include:
Rising pet ownership across the globe, with dogs and cats increasingly accepted as family members, resulting in heightened demand for preventive healthcare and routine immunization programs.
Growing awareness about zoonotic diseases and the importance of regular vaccination to protect both pets and human family members.
Technological advances in vaccine development, including recombinant, DNA‑based, and live attenuated vaccine platforms, enabling safer, more effective immunization options.
Strategic initiatives by key players such as R&D collaborations, product launches, and expansion into emerging regions, led by companies like Zoetis, Elanco and Virbac.
Market Restraints
Despite robust growth prospects, several challenges could hinder market expansion:
Limited access to veterinary services in developing regions due to economic, geographic, and infrastructural barriers, resulting in reduced vaccine uptake.
High costs of vaccine development, including research, clinical trials, and regulatory approvals, which pose significant barriers to entry for smaller firms and slow down innovation cycles.
Stringent regulatory frameworks governing vaccine safety and efficacy that can prolong time-to-market and increase investment risk.
Logistical constraints, particularly in maintaining cold‐chain integrity and ensuring broad distribution in less accessible markets.
Market Segments
Fortune Business Insights outlines the following segmentation within the companion animal vaccines market:
Product Type: Live attenuated vaccines (which hold the largest share due to durable immune response), inactivated vaccines, recombinant and DNA vaccines.
Animal Type: Canine vaccines (e.g. distemper, rabies, parvovirus), feline vaccines (e.g. feline leukemia, calicivirus), and equine vaccines for horses.
Distribution channels: Veterinary hospital pharmacies dominate, offering professional guidance and ensuring correct administration; retail and online channels are also gaining traction.
Regional Insights
In 2024, North America accounted for approximately 43.46% of the global market share, representing roughly USD 2.36 billion of the USD 5.43 billion total. This leadership position is attributed to advanced veterinary infrastructure, high pet insurance coverage, and widespread immunization protocols in the region.
Other regions—including Europe, Asia-Pacific, Latin America, the Middle East and Africa—are witnessing notable growth thanks to rising pet ownership, improving healthcare capabilities, and expanding awareness of zoonotic disease prevention. These factors suggest significant upside potential outside of North America.
Future Market Scope
Looking ahead to 2032, the companion animal vaccines market is projected to reach USD 8.71 billion at a CAGR of 6.3%.
Key future trends shaping the next phase include:
Ongoing investment in innovative vaccine platforms like recombinant and DNA vaccines, offering broader protection with improved stability and safety profiles.
Continued product launches by major players, expanding portfolios to cover emerging diseases and multi‑strain protection.
Expansion into emerging markets in Asia-Pacific and Latin America where pet adoption is rising rapidly and veterinary infrastructure is improving.
Integration with pet insurance and value‑based care models that support immunization adherence through lower financial barriers and stronger owner education.
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/industry-reports/companion-animal-vaccines-market-101041
Market Competitive Landscape
The competitive environment is dominated by major global firms such as Elanco, Zoetis, Merck Animal Health, Virbac, HIPRA, Ceva, NEOGEN and Hester Biosciences. These companies invest heavily in R&D, pursue regulatory approvals in multiple geographies, form strategic alliances, and engage in high-impact product launches.
Conclusion
The companion animal vaccines market is entering a phase of robust growth. Anchored by rising pet ownership, improved health awareness, and technical evolution in vaccine development, the global market is set to grow from USD 5.43 billion in 2024 to USD 8.71 billion by 2032 at a steady CAGR of 6.3%. Nevertheless, challenges such as regulatory complexity, high R&D costs, and distribution hurdles must be navigated wisely. Companies that can innovate while expanding access in underserved regions are poised to lead the next wave of market transformation. With strategic developments like Merck Animal Health’s NOBIVAC NXT launch enhancing product portfolios, and continued collaboration between global players, the companion animal vaccines market is well-positioned to support healthier lives for pets—and greater confidence for pet owners worldwide.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Comments